Abstract:5071 Background: Androgen deprivation therapy (ADT), such as Abiraterone Acetate (AA), has emerged as a standard treatment for metastatic prostate cancer (mPCa). However, long-term ADT treatment may increase the incidence of cardiovascular adverse events, such as hypertension, which are a common cause of death in patients receiving ADT. Therefore, it is crucial to select appropriate antihypertensive drugs that effectively manage blood pressure and improve overall survival (OS) in these patients. Methods: This study conducted a secondary analysis of the COU-AA-301 and COU-AA-302 trials, which were multicenter double-blind randomized controlled trials (RCTs) to evaluate the efficacy of AA in combination with prednisone and ADT compared to prednisone plus ADT alone in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients were retrospectively assessed and stratified based on the concurrent medication including angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) or not. OS and progression-free survival (PFS) were assessed using the Kaplan-Meier method and log-rank test. Multivariable Cox regression analysis was performed to determine the independent correlation of ACEi/ARBs with OS and PFS. Statistical significance was defined as P<0.05. Results: In COU-AA-301, the use of ACEi/ARB medications showed a significant association with improved OS (16.4 vs. 14.2 months, p<0.001) and PFS (3.1 vs. 2.9 months, p=0.002) in AA arm. After adjusting for baseline factors, ACEi/ARB medications were still found to reduce the risk of death (HR 0.72, 95% CI 0.56-0.91) and disease progression (HR 0.81, 95% CI 0.69-0.96). Similarly, in COU-AA-302, ACEi/ARB medications were associated with prolonged OS (37.4 vs. 31.9 months, p=0.003) and PFS (20.3 vs. 14.7 months, p=0.002) in AA arm. By adjusting for baseline factors, ACEi/ARB medications remained significantly associated with lower risk of death (HR 0.70, 95% CI 0.56-0.88) and disease progression (HR 0.70, 95% CI 0.55-0.88). In the placebo group, ACEi/ARB medications demonstrated improved OS only in COU-AA-301 (13.7 vs. 10.6 months, p=0.021). However, this trend did not reach statistical significance after adjusting for baseline factors (HR 0.76, 95% CI 0.55-1.03). Furthermore, the use of ACEi/ARB medications did not confer any PFS benefits in COU-AA-301 and failed to show both PFS and OS benefits in COU-AA-302. Conclusions: The use of ACEi/ARB medications has shown promise in improving OS and PFS in mCRPC patients treated with AAP. However, it is important to acknowledge the inherent limitations of post-hoc analysis, and therefore, further validation through prospective clinical trials is warranted.

Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis

Cardiovascular Toxicity Associated with Androgen Receptor Axis-Targeted Agents in Patients with Prostate Cancer: A Meta-analysis of Randomized Controlled Trials

Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis

Cardio-oncology in advanced prostate cancer

Cardiovascular Risk in Prostate Cancer

Cardiovascular Events in Prostate Cancer Treated With Novel ARSI

Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS)

A practical guide for assessing and managing cardiovascular risk during androgen‐deprivation therapy in patients with prostate cancer

Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network

Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration

Cardiovascular Toxicities of Androgen Deprivation Therapy

Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study

Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide

Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology

The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis

The Effect of ACEi/ARB on Survival Outcome of Patients with Mcrpc Treated with Abiraterone.

Effects of Radiotherapy or Radical Prostatectomy on the Risk of Long-Term Heart-Specific Death in Patients with Prostate Cancer

Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study

Cardiovascular and thromboembolic events in patients with localized prostate cancer receiving intensified neoadjuvant androgen deprivation: A systematic review and meta-analysis.

Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis

Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories